BMRI Dementia Study Recruiting Participants

Published April 7, 2015

Have you or someone you know been recently diagnosed with mild Alzheimer’s disease or Amnestic Mild Cognitive Impairment and are over age 60? You may be eligible to participate in a new clinical trial being conducted at Burke Medical Research Institute by Dr. Barry Jordan, the assistant medical director of Burke Rehabilitation Hospital and Dr. Gary E. Gibson, Director of the Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration at Burke Medical Research Institute in Westchester County, NY.

The study aims to determine if increasing brain thiamine through the use of the drug benfotiamine can help slow cognitive decline. It is a one-year trial, and requires participants to visit the Burke campus in White Plains.

Some background: The brain depends upon glucose (sugar) and oxygen much more than other tissues. A decreased ability of the brain to use glucose is a common feature in Alzheimer’s disease. The decline closely parallels diminished mental function. Thiamine (vitamin B1) is essential for normal brain glucose utilization.  Research at Burke demonstrated that thiamine dependent processes are lower in the blood and brain of patients with AD. Thus, increasing thiamine in brain may benefit patients with Alzheimer’s disease.  

The definition of Alzheimer’s disease is the presence of abnormal structures called plaques and tangles as well as memory deficits. Research done at BMRI, Weill Cornell Medical College and Mt. Sinai Medical Center shows that thiamine deficiency increases plaques and tangles in the brains of mice. Subsequent studies from BMRI/Weill Cornell Medical College and Fudan University in China demonstrate that increasing brain thiamine in mice with compounds such as benfotiamine diminishes the plaques and tangles and improves memory.

The safety of benfotiamine has already been demonstrated in humans. Diabetics are also thiamine deficient and the diminished thiamine appears to underlie the nerve damage. Large multi-center trials in Germany show that treatment with compounds such as benfotiamine, which dramatically increases thiamine levels, are beneficial in reducing the impairments caused by diabetes. Importantly, no side effects were apparent. By extension, benfotiamine is a safe way to increase thiamine brains of patients with AD.

In order to qualify for participation in the study, a number of inclusion and exclusion criteria must be met. For that criteria, as well as more details, click here.

For additional information, contact Rosanna Cirio, MA, CRC at or 914-597-2476. 

Benfotiamine in Alzheimer's Disease: A Pilot Study

Subscribe to Burke's Newsletter

Keep up with the latest news about Burke by signing up for our newsletter. 

Burke Rehab Hospital Fact Sheets

Latest Tweet